Satellos Bioscience provided early evidence that its oral Duchenne muscular dystrophy candidate is biologically active in adult patients ahead of a key readout in children later this year. The company said its Phase 2 data in adults support a rationale to pursue the pediatric program, which remains the potentially pivotal clinical decision point for Duchenne. Analysts cited the adult findings as an inflection point because Duchenne therapies often face a high bar for cross-age translation in efficacy and tolerability. The company is building a clinical case that the molecule’s mechanism and performance in adults could translate into meaningful benefit for younger patients. Investors will now focus on whether Satellos can reproduce activity and refine the dose and response profile in children, where regulators and trial end points could weigh heavily on future development and commercial positioning.